<?xml version="1.0" encoding="UTF-8"?>
<p id="par0160">It is known that administering SSHT in the above situations may cause interstitial pneumonia; therefore, use of SSHT in these situations should be avoided. In particular, because of the risk of interstitial pneumonia, using SSHT requires caution with combination with interferon. According to the COVID-19 treatment guideline of Korean Association of Internal Medicine, use of type I interferon as monotherapy is not recommended, but use of combined therapy is recommended.
 <xref rid="bib0305" ref-type="bibr">
  <sup>61</sup>
 </xref> Therefore, when considering the use of SSHT in clinical practice, it is necessary to confirm whether interferon is used or not. Moreover, there have also been case reports of pulmonary edema occurring after SSHT was used for liver dysfunction of unknown etiology.
 <xref rid="bib0310" ref-type="bibr">62</xref>, 
 <xref rid="bib0315" ref-type="bibr">63</xref> Therefore, it is necessary to pay attention to the use of SSHT when there is a liver dysfunction of unknown cause.
</p>
